Bone metabolism and fracture risk in type 2 diabetes mellitus

Endocrine Journal

Volumn 58, Issue 8, 2011, Pages 613-624

  Yamaguchi, Toru ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Adiponectin; Bone fragility; Fracture risk; Osteocalcin; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; OSTEOCALCIN; PENTOSIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; WNT PROTEIN;

ADIPOSE TISSUE; BONE DENSITY; BONE FRAGILITY; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; CLINICAL PRACTICE; DISEASE MARKER; DRUG EFFECT; FRACTURE; FRAGILITY FRACTURE; GLUCOSE METABOLISM; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; DIABETES MELLITUS, TYPE 2; FRACTURES, BONE; HUMANS; META-ANALYSIS AS TOPIC; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 80052574791     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ11-0063     Document Type: Review

References (101)

1. Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990-1047.
2. Price PA (1989) Gla-containing proteins of bone. Connect Tissue Res 21:51-57.
3. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469.
4. Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266-5270.
5. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94: 45-49.
6. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187-194.
7. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellstrom D (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24: 785-791.
8. Fernandez-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, Moreno-Navarrete JM, Fruhbeck G, Martinez C, Idoate F, Salvador J, Forga L, Ricart W, Ibanez J (2009) The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 94: 237-245.
9. Pitass AG, Harris SS, Eliades M, Stark P, Dawson- Hughes B (2009) Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 94: 827-832.
10. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew K S, Mane S, Najmabadi H, Wu D, Lifton R P (2007) LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315:1278-1282.
11. Smith U (2007) TCF7L2 and type 2 diabetes-we WNT to know. Diabetologia 50:5-7.
12. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. (2006) Nat Genet 38:320-323.
13. Owen KR, McCarthy MI (2007) Genetics of type 2 diabetes. Curr Opin Genet Dev 17:239-244.
14. LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316:1341-1345.
15. Manolagas SC, Almeida M (2007) Gone with the Wnts: ß-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 21:2605-2614.
16. Hoogeboom D, Burgering BM (2009) Should I stay or should I go: ß-catenin decides under stress. Biochim Biophys Acta 1796:63-74.
17. DeCarolis NA, Wharton Jr KA, Eisch AJ (2008) Which way does theWntblow? Exploring the duality of canonicalWnt signaling on cellular aging. BioEssays 30:102-106.
18. Jin T (2008) The WNT signalling pathway and diabetes mellitus. Diabetologia 51:1771-1780.
19. Manolagas SC (2010) From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr Rev 31:266-300.
20. Felson DT, Zhang Y, Hannan MT, Anderson JJ (1993) Effects of weight, and body mass index on bone mineral density in men and women. J Bone Miner Res 8: 567-573.
21. Glauber HS, Vollmer WM, Nevitt MC, Ensrud KE, Orwoll ES (1995) Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density. J Clin Endocrinol Metab 80: 1118-1123.
22. Yamaguchi T, Kanazawa I, Yamamoto M, Kurioka S, Yamauchi M, Yano S, Sugimoto T (2009) Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone 45:174-179.
23. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T (2007) Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol 8: 51-62.
24. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35: 842-849.
25. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2009) Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 160: 265-273.
26. Inaba M, Terada M, Koyama H, Yoshida O, Ishimura E, Kawagishi T, Okuno Y, Nishizawa Y, Otani S, Morii H (1995) Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 10:1050-1056.
27. Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T. (1997) Metabolic improvement of poorly controlled noninsulin- dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82:2915-2920.
28. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2009) Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:3031-3037.
29. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 18:427-444.
30. Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495-505.
31. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T (2007) Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Calcif Tissue Int 80:353-358.
32. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T (2009) Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications. J Bone Miner Res 24:702-709.
33. T, Yamamoto M, Kanazawa I, Yamauchi M, Yano S, Tanaka N, Nitta E, Fukuma A, Uno S, Sho-no T, Sugimoto T (2011) Quantitative ultrasound and vertebral fractures in patients with type 2 diabetes. J Bone Miner Metab (Epub ahead of print).
34. Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234.
35. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321.
36. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 114: 597-605.
37. Hernandez CJ, Tang SY, Baumbach BM, Hwu PB, Sakkee AN, van der Ham F, DeGroot J, Bank RA, Keaveny TM (2005) Trabecular microfracture and the influence of pyridinium and non-enzymatic glycationmediated collagen cross-links. Bone 37: 825-832.
38. Wang X, Shen X, Li X, Agrawal CM (2002) Age-related changes in the collagen network and toughness of bone. Bone 31: 1-7.
39. Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T (1997) Advanced glycation end-products stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 12: 439-446.
40. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S (2001) Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38: S161-S164.
41. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N (1996) Role of nonenzymatic glycosylation of type 1 collagen in diabetic osteopenia. J Bone Miner Res 11: 931-937.
42. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P (2008) Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 1126: 166-172.
43. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T (2007) The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39: 871-875.
44. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomi S (1997) Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8: 260-270.
45. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM, Mi QS (2006) Disordered osteoclast formation in RAGEdeficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 340: 1091-1097.
46. Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, Delmas PD, Bouxsein ML (2006) Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39: 1073-1079.
47. Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195-214.
48. Garnero P, Borel O, Gineyts E, Duboeuf F, Solberg H, Bouxsein ML, Christiansen C, Delmas PD (2006) Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38: 300-309.
49. Vashishth D (2007) The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 5: 62-66.
50. Banse X, Sims TJ, Bailey AJ (2002) Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 17: 1621-1628.
51. Saito M, Fujii K, Mori Y, Marumo K (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17: 1514-1523.
52. P, Fogarty J, Sell DR, Monnier VM (1992)Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41: 153-159.
53. Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA (1992) Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41: 36-41.
54. Grandhee SK, Monnier VM (1991) Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 266: 11649-11653.
55. Saito M, Fujii K, Soshi S, Tanaka T (2006) Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17: 986-995.
56. Saito M, Fujii K, Marumo K (2006) Degree of mineralization- related collagen crosslingking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 79: 160-168.
57. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A (2005) Advanced glycation end products and bone loss during aging. Ann NY Acad Sci 1043: 710-717.
58. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T (2008) Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 93:1013-1019.
59. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC; for the Health, Aging, and Body Composition Study (2009) Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 94: 2380-2386.
60. Shiraki M, Kuroda T, Shiraki Y, Tanaka S, Higuchi T, Saito M (2011) Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab 29:62-70.
61. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749.
62. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H (2001) Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108:261-268.
63. H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097-1109.
64. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Jr., Chow WS, Stern D, Schmidt AM (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-1031.
65. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T (2009) Low serum level of the endogenous secretory receptor for advanced glycation end-products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 32:2263-2268.
66. Canalis E (1983) The hormonal and local regulation of bone formation. Endocr Rev 4: 62-77.
67. Mohan S, Baylink DJ (1991) Bone growth factors. Clin Orthop Relat Res 263: 30-48.
68. Ueland T (2004) Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res 14: 404-417.
69. McCarthy TL, Centrella M, Canalis E (1989) Insulinlike growth factor (IGF) and bone. Connect Tissue Res 20: 277-282.
70. Mohan S (1993) Insulin-like growth factor binding proteins in bone cell regulation. Growth Regul 3: 67-70.
71. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL (2002) Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals and essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277: 44005-44012.
72. Johansson AG, Lindh E, Ljunghall S (1992) Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet 339: 1619.
73. Schwander JC, Hauri C, Zapf J, Froesch ER (1983) Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113: 297-305.
74. Spencer EM, Liu CC, Si EC, Howard GA (1991) In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 12: 21-26.
75. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D (2002) Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 110: 771-781.
76. T, Nishiyama K, Kuribayashi F, Chihara K(1997) Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 12 1272-1279.
77. Yamaguchi T, Kanatani M, Yamauchi M, Kaji H, Sugishita T, Baylink DJ, Mohan S, Chihara K, Sugimoto T (2006) Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int 78: 18-24.
78. Thrailkill KM (2002) Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther 2: 69-80.
79. Ahmad T, Ugarph-Morawski A, Lewitt MS, Li J, Saaf M, Brismar K (2008) Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat. Growth Horm IGF Res 18: 404-411.
80. Terada M, Inaba M, Yano Y, Hasuma Y, Nishizawa Y, Morii H, Otani S (1998) Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 22: 17-23.
81. McCarthy AD, Etcheverry SB, Cortizo AM (2001) Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 38: 113-122.
82. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2007) Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 18:1675-1681.
83. Kanazawa I, Yamaguchi T, Sugimoto T (2011) Serum Insulin-like growth factor-I is a maker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 22:1191-1198.
84. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RI (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235.
85. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M (2001) Troglitazone treatment increases bone marrow adipose tissue volume but dose not affect trabecular bone volume in mice. Calcif Tissue Int 69: 46-50.
86. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U-i, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H (2004) PPAR-? insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113: 846-855.
87. Pei L, Tontonoz P (2004) Fat's loss is bone's gain. J Clin Invest 113: 805-806.
88. MA, Miao D, Bai X-Y, Su H, Goltzman D, Karaplis AC (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183: 203-216.
89. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka- Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406.
90. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR (2007) The peroxisome proliferator- activated receptor-? agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92: 1305-1310.
91. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349-3355.
92. Kanazawa I, Yamaguchi T, Yano S, Yamamoto M, Yamauchi M, Kurioka S, Sugimoto T (2010) Baseline atherosclerosis parameters could assess the risk of bone loss in type 2 diabetes mellitus during pioglitazone treatment. Osteoporos Int 21:2013-2018.
93. Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180: 32-39.
94. SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group (2008) Rosiglitazoneassociated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31: 845-851.
95. Schwartz AV (2006) TZDs and bone: a review of the recent clinical evidence. PPAR Res 2006: 24502.
96. Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T (2010) Relationships between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab 28:554-560.
97. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14: 821-828.
98. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral adendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 1437-1443.
99. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, KhaltaevN (2005) Assessment of fracture risk. Osteoporosis Int 16: 581-589.
100. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44: 734-743.
101. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA Harris TB, Koster A, Womack CR, Palermo L, Black DM; Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group (2011) Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 305: 2184-2192.